About Relay Therapeutics
Relay Therapeutics is a publicly listed company based in Cambridge (United States) founded in 2016 by Dorothee Kern and David E Shaw. Drug discovery platform is developed to study protein motion. Relay Therapeutics has raised $520 million across 4 funding rounds from investors including ARE, SoftBank Vision Fund and Perceptive Advisors. The company has 261 employees. Relay Therapeutics has completed 1 acquisition, including ZebiAI. Its chief executive, as recorded, is Sanjiv Patel. Relay Therapeutics offers products and services including Dynamo Platform and Therapeutic Pipeline. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is RELAY THERAPEUTICS, INC. Its competitors include C4 Therapeutics, Erasca and MiRagen; 3 of its 3 listed competitors have raised funding.
Company details
Relay Therapeutics was founded in 2016 and is based in Cambridge, United States. Operations center on a drug discovery engine that generates 3D visualizations of protein mobility to analyze protein functions through motion. Ligand-binding pockets in proteins are examined, and interactions between ligands and proteins are identified. Initial efforts are directed toward oncology therapeutics.
- Headquarters Cambridge, United States
- Employees 261
- Founders Dorothee Kern, David E Shaw
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website relaytx.com
- Social LinkedIn X Instagram
- Legal Name Relay Therapeutics, Inc.
- Annual Revenue$15.36 M (USD)53.44as on Dec 31, 2025
- Net Profit-$276.48 M (USD)18.13as on Dec 31, 2025
- EBITDA-$299.18 M (USD)21.31as on Dec 31, 2025
- Total Equity Funding$520M (USD)
in 4 rounds
- Latest Funding Round$30M (USD), Post-IPO
Jan 2024
- InvestorsARE
& 12 more
- Employee Count261
- Investments & Acquisitions
Products & Services of Relay Therapeutics
Relay Therapeutics offers a comprehensive portfolio of products and services, including Dynamo Platform and Therapeutic Pipeline.
Enables visualization of protein motion for developing new therapeutics.
Advances candidates for oncology and genetic disease treatments.
Funding Insights of Relay Therapeutics
Relay Therapeutics has successfully raised a total of $520M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $30 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $520M
- Total Rounds 4
- Last Round Post-IPO — $30M
- First Round $57M
(Sep 2016)
- Investors Count 13
All 4 funding rounds of Relay Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2024 | $30M | Post-IPO | – | – | – |
| Dec 2018 | $400M | Series C | – | SoftBank Vision Fund | |
| Dec 2017 | $63M | Series B | – | BVF Partners | |
| Sep 2016 | $57M | Series A | – | Third Rock Ventures, D. E. Shaw Research | – |
13 investors in total: 13 institutional.
Investors in Relay Therapeutics
Relay Therapeutics has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, SoftBank Vision Fund and Perceptive Advisors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Corporate backed venture capital fund investing in multiple sectors | gv.com | Mountain View, United States | ||
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com | |||
US private equity investments are managed by BVF Partners. | bvflp.com | San Francisco, United States | ||
Multi-stage investment firm invests in healthcare and life sciences companies | foresitecapital.com | New York, United States | ||
Tavistock Group is engaged in global diversified investments. | tavistock.com | |||
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Venture capital investments in technology and startups. | 2016 | visionfund.com | London, United Kingdom | |
Venture capital funding is provided to early-stage life science companies. | thirdrockventures.com | Boston, United States | ||
Early stage investments focused VC firm | acks.com | |||
Tech startups are funded by S32, a venture capital entity. | s32.com | Sunnyvale, United States |
Investor details for Relay Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Relay Therapeutics
71 people are tracked at Relay Therapeutics (50 in leadership, 21 in team); the tracked headcount is 261.
| Name | Role | Group |
|---|---|---|
Dorothee Kern | Co-Founder | Leadership |
David E Shaw | Co-Founder | Leadership |
Sanjiv Patel | CEO | Leadership |
Val Dunn | Director Of Lab And Facilities Operations | Leadership |
Sanjiv K. Patel | President & CEO | Leadership |
Peter Rahmer | Chief Corporate Development Officer | Leadership |
Brian Adams | Chief Legal Officer | Leadership |
Tom Catinazzo | Chief Financial Officer | Leadership |
Don Bergstrom | President Of Research And Development | Leadership |
Surendra Singh | Vice President, Drug Substance Development And Manufacturing (cmc) | Leadership |
Arno Venter | Director | Leadership |
Drew O. | VP Head Of Nonclinical Development | Leadership |
Spenta Arnold | Vice President, R&d Portfolio Strategy & Operations | Leadership |
Kai Yu Jen | VP Clinical Science | Leadership |
Aaron Dy | Director, Business Development | Leadership |
Sophia Koutoulas | Sr Director, CMC Operations, Pharmaceutical Development | Leadership |
Colleen Chapman | Senior Director, Patient Advocacy Lead (oncology And Rare Disease) | Leadership |
Katie Otto | Director, Legal Services | Leadership |
Annie Nash Bing | Senior Director, R&d Portfolio Strategy And Operations | Leadership |
Eunice Kwak | Vice President, Clinical Development | Leadership |
51 more people are available in the full profile.
Complete people profiles for Relay Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Relay Therapeutics
Relay Therapeutics is a publicly listed company on the NASDAQ with ticker symbol RLAY in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date16 Jul 2020
- Listed onNASDAQ: RLAY
- Listed entityRelay Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS75943R1023
- Share price$17.36 (-3.45% on the day) · 2026-10-13
- Market capitalisation$3.80B
- EPS (diluted, trailing year)$-1.57
- Volume (last session)1,706,422
Financials of Relay Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $15.4M | -$276.5M | -$299.2M |
| 2024 | $10.0M | -$337.7M | -$380.2M |
| 2023 | $25.6M | -$342.0M | -$374.1M |
| 2022 | $1.4M | -$290.5M | -$306.8M |
| 2021 | $3.0M | -$363.9M | -$222.2M |
Detailed financial statements for Relay Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Relay Therapeutics
Relay Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include ZebiAI.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
AI solutions for small molecule drug discovery are provided. | zebiai.com | Waltham, United States | 2019 | Apr 2021 | $85M |
Complete acquisition details for Relay Therapeutics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Relay Therapeutics
5 dated milestones of Relay Therapeutics across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Relay Therapeutics is founded.
- Funding First funding round of $57.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires ZebiAI.
- Funding Latest funding round, Post-IPO, of $30.0M.
Competitors of Relay Therapeutics
Relay Therapeutics has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and MiRagen.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. |
Detailed competitors of Relay Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Relay Therapeutics
The website of Relay Therapeutics (relaytx.com) receives about 9.1K visits a month and ranks #2,437,145 among all websites worldwide, #3,329 in Biotechnology and Pharmaceuticals.
- Monthly visits9.1K
▲ 3% vs previous month
- Unique visitors4.2K
per month
- Global rank#2,437,145
among all websites
- Category rank#3,329
Health · Biotechnology and Pharmaceuticals
- Bounce rate40%
- Pages per visit1.8
- Average visit12 sec
- DevicesDesktop 39% · Mobile 61%
Websites whose visitors overlap most with Relay Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| oncologypipeline.com | 100% | 76.4K | #510,302 | View details | |
drugdiscoverytrends.com | drugdiscoverytrends.com | 98% | #491,427 | – | |
| exelixis.com | 98% | 39.1K | #1,001,350 | View details | |
| pharmaphorum.com | 91% | 128.2K | #451,885 | View details | |
| fiercebiotech.com | 72% | 858.3K | #81,022 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for Relay Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Relay Therapeutics (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Relay Therapeutics
Complete news archive for Relay Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Relay Therapeutics
Relay Therapeutics was founded in 2016.
Relay Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Sanjiv Patel is the CEO of Relay Therapeutics, as recorded in our data.
Relay Therapeutics is a funded company, having raised a total of $520M across 4 funding rounds to date. The company's 1st funding round was a Series A of $57M, raised on Sep 2016.
Relay Therapeutics has 261 employees.
Annual revenue of Relay Therapeutics is $15.36M as on Dec 31, 2025.
Relay Therapeutics was founded in 2016 and is based in Cambridge, United States. Operations center on a drug discovery engine that generates 3D visualizations of protein mobility to analyze protein functions through motion. Ligand-binding pockets in proteins are examined, and interactions between ligands and proteins are identified. Initial efforts are directed toward oncology therapeutics.
Relay Therapeutics's top competitors include C4 Therapeutics, Erasca and MiRagen.
Relay Therapeutics offers Dynamo Platform and Therapeutic Pipeline.
Yes, Relay Therapeutics is publicly traded on NASDAQ under the ticker symbol RLAY.
Relay Therapeutics has made 1 acquisition, including ZebiAI.
Relay Therapeutics has 13 investors. Key investors include ARE, SoftBank Vision Fund, Perceptive Advisors, Google Ventures, and Casdin Capital.